Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
Earnings Data
Report Date
Aug 08, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.1Last Year’s EPS
-0.94Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -4.56%
|Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Crinetics Pharmaceuticals, Inc. with significant progress in regulatory approvals, strong financial positioning, and preparations for the commercial launch of paltusotine. However, the decrease in revenue and increase in operating expenses present challenges.Company Guidance
In the recent call, Crinetics Pharmaceuticals, Inc. highlighted robust financial and strategic positioning for 2025, emphasizing key metrics and milestones. They reported $400,000 in revenue for Q1 2025, down from $600,000 in the same period in 2024, and noted a significant 43% increase in R&D expenses to $76.2 million, primarily driven by personnel and clinical program advancements. SG&A expenses also rose by 71% to $35.5 million, reflecting preparations for the anticipated September launch of paltusotine, a treatment for acromegaly. With $1.3 billion in cash reserves, the company is set to fund operations into 2029. The launch strategy for paltusotine focuses on establishing strong patient and payer engagement, with approximately 30 sales reps expected by summer 2025. Regulatory activities are proceeding as planned, with a decision on the paltusotine NDA expected by September 2025. The company is also advancing its pipeline with late-stage candidates and preparing for a Phase III study of adomelnet for congenital adrenal hyperplasia (CAH), reflecting a strategic focus on addressing significant unmet needs in endocrine diseases.Strong Financial Position
Crinetics Pharmaceuticals, Inc. ended the first quarter of 2025 with approximately $1.3 billion in cash, cash equivalents, and investments, expected to fund operations into 2029.
Anticipated Commercial Launch of Paltusotine
Preparations are on track for the commercial launch of paltusotine in September 2025, with positive feedback from healthcare professionals and payers.
Robust Pipeline Advancements
Advancing a robust pipeline with two late-stage candidates, an IND-cleared candidate, and three preclinical candidates, indicating strong future growth potential.
Regulatory Progress in the US and EU
No disruptions in regulatory reviews for paltusotine in the US and EU, with the European Medicines Agency granting orphan drug designation.
Positive Feedback on Paltusotine's Value Proposition
Paltusotine's value proposition is resonating well with payers, focusing on fast onset of action, durability, and ease of use.
---
CRNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $32.70 | $30.68 | -6.18% |
Feb 27, 2025 | $33.21 | $35.78 | +7.74% |
Nov 12, 2024 | $58.78 | $58.92 | +0.24% |
Aug 08, 2024 | $50.74 | $47.64 | -6.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Crinetics Pharmaceuticals (CRNX) report earnings?
Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on Aug 08, 2025, TBA Not Confirmed.
What is Crinetics Pharmaceuticals (CRNX) earnings time?
Crinetics Pharmaceuticals (CRNX) earnings time is at Aug 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRNX EPS forecast?
CRNX EPS forecast for the fiscal quarter 2025 (Q2) is -1.1.
---